Market Closed -
Nasdaq Stockholm
11:29:32 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
4.175
SEK
|
+3.34%
|
|
+0.85%
|
-34.04%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
781.4
|
2,648
|
2,669
|
1,313
|
479.4
|
316.2
|
-
|
-
|
Enterprise Value (EV)
1 |
729.3
|
2,485
|
2,553
|
1,267
|
391.2
|
200.2
|
261.2
|
280.2
|
P/E ratio
|
-25.4
x
|
-97.8
x
|
-90.2
x
|
-20.3
x
|
-3.75
x
|
-4.09
x
|
-4.8
x
|
-9.71
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
64.4
x
|
554
x
|
509
x
|
136
x
|
59.8
x
|
16.5
x
|
5.95
x
|
2.3
x
|
EV / Revenue
|
60.1
x
|
520
x
|
487
x
|
131
x
|
48.8
x
|
10.4
x
|
4.92
x
|
2.04
x
|
EV / EBITDA
|
-33.6
x
|
-127
x
|
-110
x
|
-29.1
x
|
-5.67
x
|
-3.69
x
|
-6.31
x
|
-73.7
x
|
EV / FCF
|
-17.5
x
|
-78.9
x
|
-53.3
x
|
-16.7
x
|
-8.16
x
|
-3.23
x
|
-4.28
x
|
-14.7
x
|
FCF Yield
|
-5.72%
|
-1.27%
|
-1.88%
|
-5.99%
|
-12.3%
|
-31%
|
-23.4%
|
-6.78%
|
Price to Book
|
3.55
x
|
7.84
x
|
8.66
x
|
5.25
x
|
2.01
x
|
1.23
x
|
1.62
x
|
1.87
x
|
Nbr of stocks (in thousands)
|
43,293
|
50,160
|
50,160
|
50,491
|
75,736
|
75,736
|
-
|
-
|
Reference price
2 |
18.05
|
52.80
|
53.20
|
26.00
|
6.330
|
4.175
|
4.175
|
4.175
|
Announcement Date
|
2/21/20
|
2/18/21
|
2/18/22
|
2/17/23
|
2/16/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
12.14
|
4.78
|
5.241
|
9.684
|
8.015
|
19.2
|
53.1
|
137.2
|
EBITDA
1 |
-21.69
|
-19.5
|
-23.24
|
-43.56
|
-68.98
|
-54.3
|
-41.4
|
-3.8
|
EBIT
1 |
-27.85
|
-25.68
|
-29.39
|
-64.41
|
-93.58
|
-80
|
-68
|
-32
|
Operating Margin
|
-229.41%
|
-537.15%
|
-560.83%
|
-665.15%
|
-1,167.55%
|
-416.67%
|
-128.06%
|
-23.32%
|
Earnings before Tax (EBT)
1 |
-27.89
|
-25.6
|
-29.38
|
-64.16
|
-91.46
|
-77
|
-66
|
-31
|
Net income
1 |
-27.89
|
-25.6
|
-29.38
|
-64.16
|
-102.9
|
-77
|
-66
|
-32
|
Net margin
|
-229.77%
|
-535.59%
|
-560.48%
|
-662.52%
|
-1,283.24%
|
-401.04%
|
-124.29%
|
-23.32%
|
EPS
2 |
-0.7100
|
-0.5400
|
-0.5900
|
-1.280
|
-1.690
|
-1.020
|
-0.8700
|
-0.4300
|
Free Cash Flow
1 |
-41.73
|
-31.5
|
-47.9
|
-75.92
|
-47.94
|
-62
|
-61
|
-19
|
FCF margin
|
-343.78%
|
-658.97%
|
-913.95%
|
-783.99%
|
-598.14%
|
-322.92%
|
-114.88%
|
-13.85%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/21/20
|
2/18/21
|
2/18/22
|
2/17/23
|
2/16/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
---|
Net sales
1 |
2.18
|
-
|
2.612
|
2.016
|
EBITDA
1 |
-
|
-
|
-9.805
|
-8.612
|
EBIT
1 |
-8.798
|
-
|
-15.74
|
-14.58
|
Operating Margin
|
-403.58%
|
-
|
-602.57%
|
-723.36%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-15.77
|
-14.62
|
Net income
1 |
-8.729
|
-10.73
|
-15.77
|
-14.62
|
Net margin
|
-400.41%
|
-
|
-603.71%
|
-724.95%
|
EPS
|
-0.1700
|
-0.2100
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/18/22
|
5/20/22
|
8/31/22
|
11/10/22
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
52.1
|
164
|
115
|
45.5
|
88.2
|
116
|
55
|
36
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-41.7
|
-31.5
|
-47.9
|
-75.9
|
-47.9
|
-62
|
-61
|
-19
|
ROE (net income / shareholders' equity)
|
-13.6%
|
-9.19%
|
-9.1%
|
-23%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
5.080
|
6.730
|
6.150
|
4.950
|
3.140
|
3.400
|
2.580
|
2.230
|
Cash Flow per Share
|
-
|
-0.4300
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
39.1
|
11.4
|
22.4
|
5.25
|
0.06
|
-
|
1
|
2
|
Capex / Sales
|
322%
|
238.87%
|
428.11%
|
54.22%
|
0.7%
|
-
|
1.88%
|
1.46%
|
Announcement Date
|
2/21/20
|
2/18/21
|
2/18/22
|
2/17/23
|
2/16/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -34.04% | 28.84M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|